Anna Bianchi-Smiraglia

Dr. Anna Bianchi-Smiraglia

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Molecular Cell
Verified
Journal Article
Closed access
SZShoshanna N. Zucker
Shoshanna N. Zucker
EFEmily E. Fink
Emily E. Fink
ABArchis Bagati
Archis Bagati
SMSudha Mannava
Sudha Mannava
ABAnna Bianchi-Smiraglia
Anna Bianchi-Smiraglia
MNMikhail Nikiforov
Mikhail Nikiforov

23 July 2012 in Oncogene
Verified
Journal Article
Open access
PDF file
ABAnna Bianchi-Smiraglia
Anna Bianchi-Smiraglia
SPS Paesante
S Paesante
ABAndrei V. Bakin
Andrei V. Bakin
Cancer progression, response to therapy and metastasis depend on tumor microenvironment. Integrins are cell-adhesion receptors that mediate interactions of cells with extracellular matrix. The αv-β-family of integrins contributes to tumorigenesis, response to therapy and cancer stem cell biology. Thus, understanding the function of specific integrins in cancer is critical for the development of therapeutic approaches targeting integrins. The study investigated the role of integrin β5 in breast carcinomas by depleting integrin β5 using RNA interference and reexpression of integrin β5. Depletion of integrin β5 in triple-negative breast carcinoma cells markedly reduced tumor take, growth and tumor angiogenesis, whereas reexpression of integrin β5 rescued this phenotype. Reduction in tumor angiogenesis is associated with lower expression of vascular endothelial growth factor-A in integrin β5-depleted tumors. Tumor cells deficient in integrin β5 have lower migration and proliferative capacities. Biochemical assays revealed that integrin β5 mediates the Src-focal adhesion kinase and MEK-extracellular signal-regulated kinase signaling events that operate independently, and inhibition of these pathways phenocopies integrin β5 deficiency. Breast carcinoma cells express high levels of integrin β5, whereas expression of integrin β3 is limited to stromal compartments and integrin β6 is lost in metastatic cells. Together, these findings show a critical role for integrin β5 in the tumorigenic potential of breast carcinoma cells and therapeutic targeting of integrin β5 is especially attractive for triple-negative breast carcinomas, which are refractory to most of the current therapies.

5 March 2012 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MGMegan Gervasi
Megan Gervasi
ABAnna Bianchi-Smiraglia
Anna Bianchi-Smiraglia
MCMichael Cummings
Michael Cummings
QZQiao Zheng
Qiao Zheng
DWDan Wang
Dan Wang
ABAndrei V. Bakin
Andrei V. Bakin
The process of epithelial–mesenchymal transition (EMT) in response to transforming growth factor–β (TGF-β) contributes to tissue fibrosis, wound healing, and cancer via a mechanism that is not fully understood. This study identifies a critical role of JunB in the EMT and profibrotic responses to TGF-β. Depletion of JunB by small interfering ribonucleic acid abrogates TGF-β–induced disruption of cell–cell junctions, formation of actin fibers, focal adhesions, and expression of fibrotic proteins. JunB contributes to Smad-mediated repression of inhibitor of differentiation 2 through interaction with transcription repressor activating transcription factor 3. Importantly, JunB mediates the TGF-β induction of profibrotic response factors, fibronectin, fibulin-2, tropomyosin (Tpm1), and integrin-β3, which play critical roles in matrix deposition, cell–matrix adhesion, and actin stress fibers. In summary, JunB provides important input in setting the transcriptional program of the EMT and profibrotic responses to TGF-β. Thus, JunB represents an important target in diseases associated with EMT, including cancer and fibrosis.

21 January 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
ABArchis Bagati
Archis Bagati
SMSudha Moparthy
Sudha Moparthy
EFEmily E. Fink
Emily E. Fink
ABAnna Bianchi-Smiraglia
Anna Bianchi-Smiraglia
DYDong Hyun Yun
Dong Hyun Yun
MNMikhail Nikiforov
Mikhail Nikiforov

7 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HAHayley C. Affronti
Hayley C. Affronti
ARAryn M. Rowsam
Aryn M. Rowsam
APAnthony J. Pellerite
Anthony J. Pellerite
SRSpencer R. Rosario
Spencer R. Rosario
MLMark Long
Mark Long
DSDominic Smiraglia
Dominic Smiraglia
Prostatic luminal epithelial cells secrete high levels of acetylated polyamines into the prostatic lumen, sensitizing them to perturbations of connected metabolic pathways. Enhanced flux is driven by spermidine/spermine N1-acetyltransferase (SSAT) activity, which acetylates polyamines leading to their secretion and drives biosynthetic demand. The methionine salvage pathway recycles one-carbon units lost to polyamine biosynthesis to the methionine cycle to overcome stress. Prostate cancer (CaP) relies on methylthioadenosine phosphorylase (MTAP), the rate-limiting enzyme, to relieve strain. Here, we show that inhibition of MTAP alongside SSAT upregulation is synergistic in androgen sensitive and castration recurrent CaP models in vitro and in vivo. The combination treatment increases apoptosis in radical prostatectomy ex vivo explant samples. This unique high metabolic flux through polyamine biosynthesis and connected one carbon metabolism in CaP creates a metabolic dependency. Enhancing this flux while simultaneously targeting this dependency in prostate cancer results in an effective therapeutic approach potentially translatable to the clinic.

1 October 2013 in Cell Reports
Verified
Journal Article
Open access
JWJoseph A. Wawrzyniak
Joseph A. Wawrzyniak
ABAnna Bianchi-Smiraglia
Anna Bianchi-Smiraglia
WBWiam Bshara
Wiam Bshara
SMSudha Mannava
Sudha Mannava
JAJeff Ackroyd
Jeff Ackroyd
MNMikhail Nikiforov
Mikhail Nikiforov
Melanoma is one of the most aggressive types of human cancers, and the mechanisms underlying melanoma invasive phenotype are not completely understood. Here, we report that expression of guanosine monophosphate reductase (GMPR), an enzyme involved in de novo biosynthesis of purine nucleotides, was downregulated in the invasive stages of human melanoma. Loss- and gain-of-function experiments revealed that GMPR downregulates the amounts of several GTP-bound (active) Rho-GTPases and suppresses the ability of melanoma cells to form invadopodia, degrade extracellular matrix, invade in vitro, and grow as tumor xenografts in vivo. Mechanistically, we demonstrated that GMPR partially depletes intracellular GTP pools. Pharmacological inhibition of de novo GTP biosynthesis suppressed whereas addition of exogenous guanosine increased invasion of melanoma cells as well as cells from other cancer types. Our data identify GMPR as a melanoma invasion suppressor and establish a link between guanosine metabolism and Rho-GTPase-dependent melanoma cell invasion.